Ribo Advances siRNA Delivery Beyond Liver with RiboPepSTAR™
Event summary
- Ribo presented at RNA Leaders Europe Conference on March 19, 2026.
- RiboPepSTAR™ technology enables targeted siRNA delivery to kidney, heart, and adipose tissue.
- Kidney-targeted drug enters IND-enabling phase with up to 80% gene knockdown in preclinical studies.
- Dual-target siRNAs achieve comparable knockdown levels to single-target molecules.
The big picture
Ribo's expansion beyond liver targeting with RiboPepSTAR™ aligns with the broader industry trend towards precision medicine and multi-target therapeutics. The company's success in securing over USD 6 billion in partnerships for its previous technology, RiboGalSTAR™, underscores the strategic importance of this advancement. This move positions Ribo to compete more effectively in the growing RNA therapeutics market.
What we're watching
- Clinical Translation
- How quickly Ribo can advance its kidney-targeted drug through clinical trials.
- Market Expansion
- Whether RiboPepSTAR™ can capture significant market share in renal, cardiac, and metabolic disease sectors.
- Technological Integration
- The pace at which dual-target siRNAs will be integrated into therapeutic pipelines.
Our editorial coverage:
Related topics